Immix Biopharma has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $15 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Immix Biopharma is raising $15,000,000.00 in new funding. About Immix Biopharma: Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn’s disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
To learn more about Immix Biopharma, visit http://immixbio.com/
Contact:
Ilya Rachman, Chief Executive Officer
310-651-8041
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.